MANNIN RESEARCH TO PRESENT GLAUCOMA THERAPEUTICS TREATMENT AT MEDCITY INVEST APRIL 12 -13 2016
Mannin Research is pleased to announce that it will present at MATTER Midwest University HealthTech Showcase on April 12 – 13th, 2016. Mannin Research will present and discuss its glaucoma treatment technology at the forum to an audience of sophisticated healthcare investors.
The showcase is part of the opening reception for the MedCity INVEST conference. MedCity INVEST(formerly the MidAmerica Healthcare Venture Forum) a national healthcare investing conference based in Chicago. MedCity INVEST is the premier national healthcare investing conference based in the Midwest, uniting active investors with corporate business development executives to facilitate investment opportunities with promising startups. For more than a decade, biotech, medical device, digital health, diagnostics, pharma and beyond have presented there to investors like AbbVie, Qualcomm Ventures, Mayo Clinic Ventures, Baxter, Baird, Venture Investors and beyond.
More than 300 industry leaders, venture capitalists and angel investors will be in attendance April 11 -13 to discuss investment trends and interact with a number of promising early-stage start-up companies.
As part of their involvement with the Chicago-Canada Mentorship Program (C2MP), Mannin Research will be attending the MedCity INVEST conference. Mannin Research Inc. has also been selected to participate in the MATTER Midwest University HealthTech Showcase as part of the CIM@MATTER group of companies attending. MATTER is showcasing their top healthcare technologies at the official opening reception for the MedCity INVEST Conference. For more information on the event please visit their website http://events.medcitynews.com/invest/
Mannin’s CEO, Dr. George N. Nikopoulos stated. “We are looking forward to discussing Mannin’s innovative solution for the treatment of glaucoma with industry leaders and investors at the Showcase on Monday and throughout the MedCity invest conference this week. This opportunity would not be possible without the C2MP and the CIM@MATTER program teams, and we thank them for their support.”